Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VIVUS, Inc. (VVUS): Is It Really Time To Sell?

Vivus, Inc.Biotech company VIVUS, Inc. (NASDAQ:VVUS) has struggled to pick up sales of its obesity medication Qsymia since the drug was launched in September. Last quarter, the company reported a mere $4.1 million in total revenue, and its massive selling, general, and administrative costs weighed heavily on its bottom line. In an effort to encourage both physician and patient adoption, VIVUS, Inc. (NASDAQ:VVUS) has not only established two free trial programs, but has also launched the “Q and Me” mobile app, whose aim is to help patients comply with their prescribed weight loss treatment, track food intake, and set exercise goals.

While Qsymia was the first obesity medication to hit the market in more than a decade, VIVUS, Inc. (NASDAQ:VVUS)’ app wasn’t the first to help patients manage their weight. Recently, Motley Fool health-care analyst Max Macaluso spoke with Dr. Domenica Rubino, a weight-management expert and representative of The Obesity Society. In the following video, Dr. Rubino discusses technologies that can be used to help track and manage weight loss. A transcript follows the video.

Is now the time to sell VIVUS?
VIVUS, Inc. (NASDAQ:VVUS)’ shares were clobbered after Qsymia’s dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool’s top health-care contributor breaks down this complex story and explains the details VIVUS investors must know — including reasons to buy and sell. To find out more about this premium report click here now.

Max Macaluso: Hi, welcome to The Motley Fool. I’m Max Macaluso, and I’m talking with Dr. Domenica Rubino, a representative of the Obesity Society and a practicing physician in weight management. Welcome.

Domenica Rubino: Thank you.

Macaluso: We spoke in a previous segment about how drugs can help obese patients lose weight, and exercise and diet are also very important in that process. What are some technologies that can help people also manage their weight?

Rubino: Max, actually there are quite a few technologies that can be very helpful. First of all, there are a lot of apps now that are available. Most people carry a smartphone.

Fundamentally, what’s important about these technologies is to remain mindful about what you’re doing — to record what you’re eating, record your exercise, to really help you stay focused and structured.

Macaluso: Tracking your progress.

Rubino: Absolutely. You can track your progress in terms of weight.

These apps can do that. You can record your food intake, record your exercise, and also track your progress in terms of your weight loss. That can be very helpful.

In addition to apps, a very simple thing is a pedometer that people wear on their waistband or in their chest pocket. What it does is measure your strides every day, and your steps every day. It can tell you how many calories.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.